全身性筋力低下を伴う重症筋無力症患者におけるARGX-113の安全性および忍容性に関する研究。

基本情報

NCT ID

NCT03770403

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

151

治験依頼者名

argenx

概要

This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.

対象疾患

介入

依頼者（Sponsor）